Background: Mutations in GRN (progranulin) and MAPT (microtubule-associated protein tau) are among the most frequent causes of monogenic frontotemporal dementia (FTD), but data on the frequency of these mutations in regions such as Latin America are still lacking.
A n autosomal-dominant pattern of inheritance is observed in around 10% to 15% of the frontotemporal dementia (FTD) cases. 1, 2 Mutations in >10 genes are currently known to be causative of monogenic forms of FTD, but the most commonly reported worldwide are found in GRN (progranulin), MAPT (microtubule-associated protein tau), and C9orf72 (chromosome 9 open reading frame 72). 3 GRN mutations cause disease through haplo-insufficiency, and progranulin levels are low in the plasma and the cerebrospinal fluid of mutation carriers. 4, 5 Frequencies of MAPT and GRN mutations in FTD cohorts around the world have been published, and results vary significantly. The frequency of GRN mutations in Italy, for example, was 15.6% in 1 study, whereas it was 1.6% in Japan. 6, 7 Frequencies of MAPT mutations in FTD cohorts were 17.9% in a British study and 4.7% in a French study. 3, 8 World regions such as Latin America and Africa, however, have been largely understudied and data are still scarce on monogenic FTD in these regions.
In this study, we aimed to determine the frequencies of GRN and MAPT mutations in FTD cohorts seen in 2 of Brazil's largest dementia research centers, and characterize the demographic, clinical, and neuropathologic features of mutation carriers. We also used plasma progranulin levels to detect null mutations in GRN, and aimed to determine a cutoff value for our population.
METHODS

Population
We included patients diagnosed with behavioral-variant FTD (bvFTD, n = 55), semantic-variant primary progressive aphasia (svPPA, n = 11), or nonfluent-variant PPA (nfvPPA, n = 10), with or without motor neuron disease (MND), on the basis of current diagnostic criteria. 9, 10 Four probands had FTD-MND. Patients were seen at the dementia clinics from the University of Sao Paulo (USP cohort) or from the Federal University of Minas Gerais (UFMG cohort), or elsewhere (ie, private offices) by researchers affiliated with either 1 of those 2 institutions. A family history was considered positive for FTD if at least 1 first-degree relative was diagnosed with or had symptoms suggestive of FTD on the basis of information obtained from family members.
Individuals who did not have neurological or psychiatric comorbidities, did not have cognitive complaints or evidence of functional decline, and obtained a score above education-adjusted cutoff values on the mini-mental status examination (MMSE) 11 were selected for the control group. MMSE cutoff scores were as follows: Z18 for illiterates, Z24 for individuals with 1 to 7 years of schooling, and Z26 for individuals with 8 or more years of schooling.
Gene Sequencing
DNA was extracted from peripheral blood leukocytes using previously described methods. 12 For each PCR reaction, we used 12.5 mL of PCR MasterMix (Thermo Scientific), 4.5 mL of autoclaved DEPC-treated water, 2 mL of each primer (forward and reverse), 13, 14 and 4 mL of DNA (50 ng/mL). We used touchdown protocols in an Eppendorf Mastercycler Pro thermocycler (protocols available upon request). Sanger sequencing of exons 1, 9 to 13 of MAPT, and 1 to 12 of GRN was performed in an ABI 3130Xl Genetic Analyzer (Applied Biosystems). Sequencing data were analyzed with Mutation Surveyor v3.2 (SoftGenetics).
Plasma Progranulin
Blood was centrifuged at 1000g for 15 minutes on the same day of blood collection, and plasma was stored at À201C. Plasma progranulin levels were measured using a human Progranulin ELISA kit (Adipogen), following the manufacturer's instructions. Plates were read at 450 nm with the Synergy HT (Biotek) reader.
Statistical Analyses
To compare groups, we used the Kruskal-Wallis or the Wilcoxon Mann-Whitney tests, depending on the number of groups analyzed. For categorical variables, we used the w 2 test. Significance was set at P < 0.01. Statistical analyses were performed with Stata 12.1 (StataCorp LP).
Neuropathologic Assessment
The brain was fixed in 10% buffered paraformaldehyde for 14 to 21 days. Brain regions were sampled from the fixed hemispheres, embedded in paraffin, and sectioned at 5 mm thickness for staining. Areas included the frontal pole, the anterior orbital gyrus, the amygdala at the level of mammillary bodies, the middle and the inferior frontal gyri, the ventral striatum, the superior, the middle, and the inferior temporal gyri, the insula, the basal ganglia at the level of the anterior commissure, the superior frontal sulcus, hippocampal formation at the level of the lateral geniculate body, the sensorimotor cortex, the thalamus, the angular gyrus, the calcarine cortex, the cerebellum with a dentate nucleus, the midbrain, rostral and caudal pons, and the rostral medulla. All areas were stained with hematoxylin and eosin, and selected sections were immunostained with antibodies against b-amyloid (4G8, 1:10.000; Signet Pathology Systems, Dedham, MA), phospho-tau (PHF-1, 1:2.000; gift of Peter Davies, NY), TDP-43 (1:500, Proteintech, Chicago, IL), and a-synuclein (EQV-1, 1:10.000; gift of Kenji Ueda, Tokyo, Japan).
This study was approved by the local Ethics Committee, and informed consent forms were signed before blood draw.
RESULTS
Clinical and demographic features of the cohorts are shown in Table 1 . Seventy-six probands were included in this study (62 from the USP cohort and 14 from the UFMG cohort). Nineteen of the probands (25%) had a positive family history for FTD. Only 1 individual from a family (proband) was included in Table 1 . The control group was composed of 60 individuals who did not carry pathogenic mutations in GRN or MAPT (Table 1 ).
GRN Mutations
Null GRN mutations were identified in 7 probands ( Table 2 ). Of these, 3 are novel (p.Q130X in proband USP 22, p.D317Afs*12 in proband USP 63, and p.K259Afs*23 in proband UFMG 18) and will be presented in detail below.
Proband USP 11 was diagnosed with nfvPPA. Her family history was negative for FTD, but her mother was diagnosed with early-onset Alzheimer's disease (AD) after presenting with memory problems and apathy at age 63 years. Proband USP 22 was diagnosed with nfvPPA, and her brother developed bvFTD at age 57 years. Their mother died with a diagnosis of early-onset AD. Proband USP 53 was diagnosed with nfvPPA, but also had severe impairment of semantic memory, and hence could be classified as having mixed PPA. 15 Proband USP 64 was diagnosed with bvFTD. His mother was also diagnosed with bvFTD, with the onset of symptoms at age 58 years and death at age 69 years. A first-degree cousin developed bvFTD at age 59 years and died at age 70 years, but the cousin's mother died at age 87 years without clear signs of cognitive impairment.
The frequency of GRN mutations was 9.6% (6/62) in the USP cohort and 7.1% (1/14) in the UFMG cohort. The frequency in the combined cohort was 9.2% (7/76). 
GRN p.Q130X
Proband USP 58 started with memory problems and topographic disorientation when she was 50 years old. She was first seen 2 years later, and scored 19 on the MMSE. Her brain magnetic resonance imaging (MRI) showed global atrophy and FDG-PET showed hypometabolism in the frontal, the temporal, and the parietal regions, and in the anterior cingulate area. She was first diagnosed with possible AD, but later developed symptoms consistent with bvFTD, such as loss of empathy, irritability, and hyperphagia. Language problems also appeared, and were characterized by a nonfluent speech, with syntax errors and phonemic paraphasias. Her symptoms worsened over time, and 5 years after the onset of symptoms, she was practically mute and was dependent for all basic daily life activities.
Her sister was also diagnosed with bvFTD, and carried the same mutation. At the age of 54 years, she developed difficulty with planning and organizing, excessive shopping, and changes in eating behavior. Her score on the MMSE was 19 one year after onset of symptoms. She later developed delusions and parkinsonism (while using an atypical antipsychotic). Her MMSE score was 8 two years after onset of symptoms. Her brain MRI scans are shown in Figure 1 . FLAIR sequence images show progressive atrophy over the course of the disease (the first scan was performed in her first year of symptoms), accompanied by white-matter hyperintensities that were absent in the first scan and appeared gradually.
The proband's mother died of pulmonary embolism at age 60 years, without signs of cognitive impairment. Her maternal grandmother had presenile dementia, with onset around the age of 50 years.
GRN p.D317Afs*12
Proband USP 63 developed behavioral changes characterized by disinhibition, apathy, impulsivity, and overspending when he was 52 years old. He was first evaluated at age 54 years, and scored 29 on the MMSE. The neurological examination did not show signs of parkinsonism or motor changes. His brain MRI showed bilateral frontal atrophy, worse on the right side (Fig. 1) , and brain SPECT showed bilateral frontal hypoperfusion. He was diagnosed with bvFTD.
His symptoms worsened gradually. Around 4 years after symptom onset, the neurological examination showed parkinsonism and dystonic posturing of limbs during gait. He died 15 years after disease onset, at age 67 years.
The brain was collected at the Brazilian Brain Bank of the USP Medical School. The unfixed brain weight was 802 g (Fig. 2) . Macroscopic examination showed asymmetric global cortical atrophy most significant in the frontal, the temporal, and the parietal lobes. Microscopical examination was performed on the right hemisphere. Immunohistochemistry against hyperphosphorylated TDP-43 (mouse monoclonal MAb 409/410, 1:1000; Cosmo Bio, Tokyo, Japan) showed the presence of an immunoreactive pathology. Neuronal cytoplasmic inclusions and short dystrophic neurites were observed in the frontotemporal cortex predominantly in layer 2. In addition, a few neuronal cytoplasmic inclusions were detected in dentate granule cells of the hippocampus. Neuropathologic findings were consistent with FTLD-TDP (Frontotemporal lobar degeneration with TDP-43-positive inclusions) type A. 16 The proband's mother developed symptoms consistent with nfvPPA when she was 77 years old. Two years later, she developed behavioral symptoms, such as a lack of empathy, signs of poor judgment, and apathy. A brain MRI showed frontal perisylvian atrophy, slightly worse on the left hemisphere, and periventricular white-matter hyperintensities. About 5 years after the onset of symptoms, parkinsonian signs with gait abnormalities were noticed. She is currently alive, at age 89 years, but is mute and unable to stand or walk.
GRN p.K259Afs*23
Proband UFMG 18 was a male patient who presented with word-finding difficulties at age 69 years. He had 16 years of schooling. On neurological examination, his MMSE score was 26/30, with mild impairment in confrontation naming and category fluency. His gait was normal, and no motor or sensory changes were observed. The brain MRI did not show any abnormality at the time. Slow deterioration of naming was recorded, with increasing interference in his professional activities. Apathetic behavior emerged 1 year after the first examination, followed by disinhibition 6 months later. Eating changes (preference for sweets) were also reported. This clinical picture worsened progressively. MRI revealed marked atrophy of the anterior and the medial parts of the left temporal lobe (Fig. 1) . He was diagnosed with bvFTD. Three years after the first examination, he scored 11/30 on the MMSE, with marked reduction in verbal fluency. No motor or sensory changes were observed.
His family history was positive for bvFTD. His father died with bvFTD at age 77 years, 5 years after the onset of symptoms. Two of his siblings were also diagnosed with bvFTD. One of his 2 brothers developed symptoms at age 66 years, and died at age 70 years and his sister's symptoms began at age 64 years. She died when she was 75 years old. The proband's cousin was also diagnosed with bvFTD and carried the same mutation. At age 70 years, he presented with a 12-month history of memory deficits, word-finding difficulties, and logorreic speech. Other medical problems included obstructive sleep apnea, 1 episode of syncope of unknown etiology, and Paget's disease of the bone. On neurological examination, his MMSE score was 27 (loss of 3 points on word recall), with mild impairment in confrontation naming and category fluency [semantic verbal fluency animal category = 11, phonemic verbal fluency (FAS) = 31, and Boston naming test 39/60]. Gait was normal without clinical signs of cerebrovascular disease, parkinsonism, or MND. Brain MRI showed white-matter hyperintensities, which were interpreted to be due to microangiopathy. Deterioration of language and apathy was noticed in the following 12 months with interference with his daily activities (MMSE score 24). Three years later, he presented with marked clinical deterioration, especially on verbal fluency [MMSE 22, semantic verbal fluency animal category = 6, phonemic verbal fluency (FAS) = 19], stereotypical speech without any change in neurological examination. MRI revealed marked atrophy of the anterior and the medial parts of the left temporal lobe.
MAPT Mutations
Two probands had mutations in MAPT ( Table 2) . Proband USP 17 was initially diagnosed with bvFTD, but later developed a PSP-like (progressive supranuclear palsy) phenotype. Four of his siblings had died after developing similar behavioral and motor symptoms (suggestive of PSP). Proband UFMG 23 was diagnosed with bvFTD, and had a deceased sister who had developed dementia with frontotemporal features.
The frequency of MAPT mutations in the USP cohort was 1.6% (1/62), and in the UFMG cohort was 7.1% (1/14) . The frequency in the combined cohorts was 2.6% (2/76).
Plasma Progranulin Levels
Means, SDs, and the range of plasma progranulin levels are shown in Figure 3 . We included plasma samples from the control group (n = 60), the USP FTD cohort (55 GRN À probands, 4 GRN + probands, and 3 symptomatic GRN + relatives) and 2 individuals from the UFMG FTD cohort (n = 2, proband UFMG 18 and a symptomatic first-degree cousin who carried the same mutation). Plasma samples from probands USP 58 and USP 63 were not available, but we obtained plasma from the sister of proband USP 58 and mother of proband USP 63 (as well as from the brother of proband USP 22) .
Plasma progranulin levels were significantly lower in the FTD group with null GRN mutations (FTD GRN +) than in the FTD group without GRN mutations (FTD GRN À , P < 0.0001) or in the control group (P < 0.0001). Nonparametric ROC analysis (FTD GRN + vs. FTD GRN À and control) showed a cutoff value of r70 ng/mL, and indicated null GRN mutations with 100% sensitivity and specificity.
Plasma progranulin levels were also lower in the FTD GRN À group in comparison with the control group (P < 0.0001). The FTD GRN À and the control groups were matched for age at blood draw and sex (P = 0.96 and 0.127, respectively).
DISCUSSION
The frequency of GRN mutations in this Brazilian FTD cohort was 9.6%, and among familial FTD cases, the frequency was 31.5%. MAPT mutations were found in 7.1% of the FTD cases and 10.5% of the familial FTD cases. We did not find GRN or MAPT mutations in sporadic FTD, but one proband's (USP 11) family history included only a mother diagnosed with early-onset AD (and therefore was not considered as having familial FTD). Three of the GRN mutations (p.Q130X, p.D317Afs*12, and p.K259Afs*23) were not previously reported in FTD, highlighting the importance of studying genetics in different populations. This is the first study on the frequency of GRN and MAPT mutations in South-American FTD cohorts.
The frequency of GRN mutations in this cohort is within the range reported by North-American and European studies (3% to 15%), 3, 6, 8, [17] [18] [19] [20] but higher than that reported by Asian groups (0% to 1.6%). 7, 21, 22 Among familial FTD cases, the frequency of GRN mutations is higher than that reported by other groups, such as studies conducted in Northern Italy (24.8%), United Kingdom (20%), or France (14%). 3, 6, 8 Similarly, the frequency of MAPT mutations in our cohort is within the range published by groups from the United States, Japan, and European countries (4.7% to 17.9%). 3, 7, 8, [17] [18] [19] MAPT mutations were absent in Korean and Indian cohorts. 21, 22 A subset of the USP FTD cohort (n = 47) was screened for TARDBP mutations, and a p.I383V mutation was identified in a proband diagnosed with svPPA. 23 The GRN p.Q130X mutation is a nonsense mutation found in 2 sisters diagnosed with bvFTD, one of whom had low levels of plasma progranulin (25 ng/mL). Although it has not been reported in patients with FTD, the mutation was identified in a tissue sample of a 63-year-old man with large-intestine carcinoma in the COSMIC catalog of somatic mutations in cancer (COSM187683). 24 No data are available on cognitive symptoms.
The GRN p.D317Afs*12 mutation was identified in a proband diagnosed with bvFTD, who developed symptoms at age 52 years and died 15 years later. The neuropathologic assessment revealed changes compatible with FTLD-TDP type A, which is the subtype typically associated with GRN mutations. 16 The proband's mother was also tested for GRN mutations, and carries the same mutation; her plasma progranulin level was low (48.4 ng/mL). Further corroborating the pathogenicity of this mutation, the SIFT indel algorithm predicted nonsense-mediated messenger RNA decay caused by the GRN g.11444-11445delAC mutation. 25 The GRN p.K259Afs*23 mutation was found in a proband diagnosed with bvFTD. The SIFT indel algorithm also predicted nonsense-mediated messenger RNA decay caused by g.10981-10984delAAGT. 25 Sequencing GRN in a first-degree cousin of the proband, diagnosed with bvFTD, revealed the same mutation, indicating segregation with disease. Moreover, as expected for a null GRN mutation, plasma progranulin levels were low in both patients (17.1 ng/mL in the proband and 60.2 ng/mL in his cousin), which provides further evidence of pathogenicity.
The remaining GRN null mutations (GRN p.Q300X, p.V200Gfs*18, p.Q257Pfs*27, and p.S301Cfs*61) have been reported elsewhere, in British (p.Q300X), French (p.V200Gfs*18), Swedish (p.V200Gfs*18), Canadian (p.V200Gfs*18), and Portuguese (p.Q257Pfs*27 and p.S301Cfs*61) FTD cohorts. 8, 20, [26] [27] [28] [29] [30] [31] Of note, the Canadians patients with the GRN p.V200fs*18 mutation were 2 sisters of Chinese ancestry diagnosed with corticobasal syndrome. 29 The observation that 2 of the mutations we found in this study (GRN p.Q257Pfs*27 and GRN p.S301Cfs*61) have been reported only in Portuguese FTD cohorts is interesting, but not entirely unexpected, considering Brazil´s history as a Portuguese colony. 26, 31 The maternal grandfather of proband USP 64 was born in Portugal and emigrated to Brazil in the beginning of the 20th century.
The clinical presentation of GRN-associated disease was highly variable, which is in line with previous reports. 27, 32 Three of the probands were diagnosed with nfvPPA, whereas the other 4 probands were diagnosed with bvFTD. GRN mutations were found in 7.2% (4/55) of the bvFTD cases and 30% (3/10) of the nfvPPA cases. No GRN mutations were identified in svPPA or FTD-MND cases. There was also significant intrafamilial heterogeneity. Proband USP 63, for example, developed symptoms at an age 25 years earlier than his mother. Similarly, Rademakers et al 32 observed families in which the age at onset or death occurred 10 to 20 years later in a parent than in the proband.
Neuroimaging studies have reported white-matter abnormalities in 20% to 40% of the GRN mutation carriers. 30, 31 We observed periventricular white-matter hyperintensities in 4 of the 6 mutation carriers from whom FLAIR/T2-weighted MRI scans were available. As shown in Figure 2A , however, white-matter changes may be absent in the early stages of the disease and appear only in areas of maximal atrophy as the disease progresses.
In this study, we found that plasma progranulin levels r70 ng/mL identified null GRN mutations with 100% sensitivity and specificity. This cutoff value is similar to the one reported by Ghidoni et al 4 (61.55 ng/mL), but lower than the value suggested by Finch et al 5 (112 ng/mL). Upon reviewing the data reported by groups that also used the Adipogen ELISA kit to measure progranulin levels in the plasma, we found significant variability across studies. In controls, the mean plasma progranulin level varied between 169 and 228 ng/mL, and the measurements ranged between 61.8 and 473.4 ng/mL. 4, 5, 33, 34 Among null GRN mutation carriers, plasma progranulin levels ranged from 10.9 to 107.8 ng/mL. 4, 5, 35 Of note, the higher end of this range is close to the mean value we found in the FTD group without GRN mutations (109 ng/mL). The reasons for these discrepancies are not clear, but are likely due to different demographic characteristics of the cohorts (age and sex are known to affect plasma progranulin levels) as well as other genetic factors that influence progranulin expression. 36 It should be noted that the Brazilian population has significant genetic admixture and it is possible that the frequencies of genetic polymorphisms that influence plasma progranulin levels differ in our population, and this could explain at least in part our findings (even though this has not been formally tested).
Both MAPT mutations (p.N279K and IVS10 + 16 C > T) have already been reported, and were found in 2 probands with bvFTD (3.6% of the bvFTD cases). Mutations in MAPT were not identified in probands with nfvPPA, svPPA, or FTD-MND. The MAPT p.N279K mutation was identified in a patient (USP 17) who first developed behavioral symptoms suggestive of bvFTD, but later showed axial-predominant parkinsonian features and eye-movement abnormalities consistent with a diagnosis of PSP. The PSP phenotype is the most commonly reported presentation of this mutation. 7, 36 The p.N279K mutation was reported in a large North-American kindred diagnosed with pallido-ponto-nigral degeneration, and also in French, Italian, and Japanese families. 7, 37, 38 The IVS10 + 16C > T is one of the most common MAPT mutations reported worldwide, and was identified in at least 27 families. 39 Patients with this mutation are more often diagnosed with bvFTD (such as the proband UFMG 23), but an AD-like phenotype has also been reported. 40 In conclusion, frequencies of GRN and MAPT mutations in this Brazilian FTD cohort were 9.6% and 7.1%, respectively. GRN mutations were particularly frequent among familial FTD cases, in a frequency (31.5%) that is higher than that found by other groups. Three novel null GRN mutations were identified (p.Q130X, p.D317Afs*12, and p.K259Afs*23), and were reported with solid evidence of pathogenicity. A plasma progranulin cutoff value of 70 ng/mL was associated, with 100% sensitivity and specificity to detect null GRN mutations, although a study with a larger sample of Brazilian FTD patients and controls would be necessary to corroborate this finding.
